SG11201807783UA - Mutant bordetella strains and methods for use - Google Patents

Mutant bordetella strains and methods for use

Info

Publication number
SG11201807783UA
SG11201807783UA SG11201807783UA SG11201807783UA SG11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA
Authority
SG
Singapore
Prior art keywords
lille
international
subject
institut
calmette
Prior art date
Application number
SG11201807783UA
Inventor
Luis Solans
Camille Locht
Anne Tsicopoulos
Yahia Sendid Saliha Ait
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of SG11201807783UA publication Critical patent/SG11201807783UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M1111101110101011111 HO 11111 01110111100111 11111001111111101111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/167834 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 35/00 (2006.01) A61P 11/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/057468 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 29 March 2017 (29.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/314,843 29 March 2016 (29.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: INSTITUT PASTEUR DE LILLE [FR/FR]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 1 me du Professeur A. Calmette, BP 245, 59019 Lille Ce- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, dex (FR). INSTITUT NATIONAL DE LA SANTE ET TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DE LA RECHERCHE MEDICALE (INSERM) DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [FR/FR]; 101, Rue de Tolbiac, Cedex, 75654 Paris (FR). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: SOLANS, Luis; 21, Rue Gay Lussac, Apt. 61, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 59110 Le Madeleine (FR). LOCHT, Camille; Institut Pas- teur de Lille, 1, me du Prosfessor A. Calmette, BP 245, Published: 59019 Lille Cedex (FR). TSICOPOULOS, Anne; Institut — with international search report (Art. 21(3)) Pasteur de Lille, 1, me du Prosfesseur A. Calmette, BP 245, 59019 Lille Cedex (FR). AIT YAHIA SENDID, Sa- — with (an) indication(s) in relation to deposited biological liha; Institut Pasteur de Lille, 1, rue du Professeur A. material furnished under Rule 13bis separately from the Calmette, BP 245, 59019 Lille Cedex (FR). description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) Agents: KILBURN & STRODE LLP et al.; 20 Red Lion — with sequence listing part of description (Rule 5.2(a)) = (74) Street, London WC1R 4PJ (GB). 1-1 7r M GC IN 1-1 (54) Title: MUTANT BORDETELLA STRAINS AND METHODS FOR USE 1-1 C (57) : A method of reducing or preventing the development of airway inflammation in a subject includes the step of infect - ei ing the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated en. ) pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflamma- tion in the subject.
SG11201807783UA 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use SG11201807783UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Publications (1)

Publication Number Publication Date
SG11201807783UA true SG11201807783UA (en) 2018-10-30

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807783UA SG11201807783UA (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Country Status (8)

Country Link
US (4) US10682377B2 (en)
EP (1) EP3436034A1 (en)
JP (1) JP6993984B2 (en)
CN (2) CN109069535B (en)
AU (2) AU2017242541B2 (en)
CA (1) CA3018126A1 (en)
SG (1) SG11201807783UA (en)
WO (1) WO2017167834A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1994139T3 (en) 2006-03-10 2016-10-24 Pasteur Institut Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
JP5678034B2 (en) 2009-04-28 2015-02-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Vaccines for the prevention or treatment of allergen-driven airway conditions
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use
WO2019077028A1 (en) * 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (en) 1994-04-19 1996-06-14 Pasteur Institut Recombinant proteins of the filamentous hemagglutinin of Bordetella, in particular, B. Pertussis, production and application to the production of foreign proteins or vaccinating active principles.
DK0755403T3 (en) * 1994-04-28 2000-02-14 Takeda Chemical Industries Ltd Method of separating protective components from Bordetalla pertussis
FR2754543B1 (en) * 1996-10-11 1998-12-31 Pasteur Institut BORDETELLA STRAIN DEFICIENT IN TOXIN PRODUCTION AND EXPRESSING HYDRID PROTEIN, LIPOSOMES COMPRISING FHA AND THEIR USES AS VACCINES, AND THE USE OF FHA TO STIMULATE IMMUNE RESPONSES
FR2840319B1 (en) 2002-05-30 2004-08-20 Pasteur Institut BORDETELLA STRAINS MADE DEFICIENT BY GENETIC ATTENUATION
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc Methods of preventing or treating respiratory conditions
DK1994139T3 (en) 2006-03-10 2016-10-24 Pasteur Institut Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
ES2562774T3 (en) 2006-11-15 2016-03-08 Folia Biotech Inc. Flu vaccines based on the papaya mosaic virus
WO2008118592A2 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
CN101790534A (en) 2007-06-18 2010-07-28 半球生物制药公司 Early intervention of viral infections with immune activators
JP5678034B2 (en) * 2009-04-28 2015-02-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Vaccines for the prevention or treatment of allergen-driven airway conditions
CN102802665B (en) 2009-06-15 2015-11-25 新加坡国立大学 Influenza vaccines, compositions and using method
US9415077B2 (en) 2011-11-02 2016-08-16 Institut National De La Sante Et De La Recherche Medicale Effect of an attenuated Bordetella strain against allergic disease
CN102793915B (en) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 Production method of acellular pertussis vaccine
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use

Also Published As

Publication number Publication date
CA3018126A1 (en) 2017-10-05
JP2019513722A (en) 2019-05-30
US10682377B2 (en) 2020-06-16
CN109069535A (en) 2018-12-21
US20210290667A1 (en) 2021-09-23
EP3436034A1 (en) 2019-02-06
US20200323901A1 (en) 2020-10-15
WO2017167834A1 (en) 2017-10-05
AU2017242541B2 (en) 2022-06-30
US20230381224A1 (en) 2023-11-30
AU2017242541A1 (en) 2018-10-11
CN114767718A (en) 2022-07-22
US11065276B2 (en) 2021-07-20
AU2022221438A1 (en) 2022-10-06
CN109069535B (en) 2022-03-18
JP6993984B2 (en) 2022-02-03
US20170283890A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
SG11201807783UA (en) Mutant bordetella strains and methods for use
SG11201807195VA (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201804934PA (en) Novel Compounds
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201805835WA (en) Modified oncolytic virus
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201805072PA (en) Nicotine powder delivery system
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201811250TA (en) Nicotine inhaler system
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901351UA (en) A patient interface, system and method
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion